Outcome After Avascular Necrosis of the Femoral Head in Young Patients (AVN)
Outcome After Avascular Necrosis of the Femoral Head in Young Patients - Retrospective Analysis With a Min. 10-year Follow-up
- The course of AVN between Initial diagnosis and total hip replacement (THA) is analysed. The impact of early interventions versus conservative therapy in AVN before THA will be evaluated.
- The short and long term outcomes of AVN patients undergoing THA with respect to complications, reoperations and quality of life are investigated. Potential risk factors for adverse outcomes will be investigated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is to describe the course of avascular necrosis (AVN) of the femoral head from initial diagnosis and to collect data on treatment options and the further course in these cases. The duration from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA) will be analysed and the course after joint replacement with potential short- and long-term complications will be evaluated.
The impact of THA after AVN on activities of daily living will be assessed by Euroquol 5 Dimensions (EQ-5D-5L) and Hip disability and Osteoarthritis Outcome Score (HOOS) questionnaires.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Population 1: Patients with a first AVN-related contact (initial or confirmed diagnosis) at the USB or KSBL Liestal in the years between 1999-2006.
Population 2: Patients with a THA because of AVN at the USB or KSBL Liestal in the years 2000-2007.
Description
Inclusion Criteria:
- MRI of the hip available from diagnosis at the USB or KSBL Liestal
- Informed Consent
Exclusion Criteria:
- Insufficient knowledge of project languages (English, German, French)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Population 1
Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
|
questionnaires with respect to outcomes:
questionnaires to assess course of the disease:
|
|
Population 2
Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
|
questionnaires with respect to outcomes:
questionnaires to assess course of the disease:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
arthroplasty-free interval (time until THA)
Time Frame: single time point assessment at baseline
|
time from first diagnosis of AVN to joint replacement = time to event data (in the years between 1999-2006)
|
single time point assessment at baseline
|
|
rate of reoperations after THA
Time Frame: single time point assessment at baseline
|
reoperation after THA = time to event data (in the years between 2000-2007)
|
single time point assessment at baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hip disability and Osteoarthritis Outcome Score (HOOS)
Time Frame: single time point assessment at baseline
|
40 item questionnaire to assess patient-relevant outcomes in five separate subscales (pain, symptoms, activity of daily living, sport and recreation function and hip related quality of life).
Scores are: None, Mild, Moderate, Severe, Extreme
|
single time point assessment at baseline
|
|
Euroquol 5 Dimensions (EQ-5D-5L)
Time Frame: single time point assessment at baseline
|
Five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
|
single time point assessment at baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Franziska Saxer, Dr. med, Dep. of Orthopedic and Trauma Surgery; University Hospital Basel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-01264; ch18Saxer3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.